Jerome Henri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4216800/publications.pdf

Version: 2024-02-01

		1163117	996975
17	235	8	15
papers	citations	h-index	g-index
17	17	17	345
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Permeability of the Cyanotoxin Microcystin-RR across a Caco-2 Cells Monolayer. Toxins, 2021, 13, 178.	3.4	6
2	A PBPK model to study the transfer of α-hexabromocyclododecane (α-HBCDD) to tissues of fast- and slow-growing broilers. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2020, 37, 316-331.	2.3	6
3	A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion. Pharmaceutical Research, 2018, 35, 92.	3.5	10
4	Lack of experimental evidence to support mcr-1 -positive Escherichia coli strain selection during oral administration of colistin at recommended and higher dose given by gavage in weaned piglets. International Journal of Antimicrobial Agents, 2018, 51, 128-131.	2.5	5
5	The present and future of withdrawal period calculations for milk in the European Union: dealing with data below the limit of quantification. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 116-122.	1.3	6
6	A physiologically based pharmacokinetic model for chickens exposed to feed supplemented with monensin during their lifetime. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 370-382.	1.3	35
7	The present and future of withdrawal period calculations for milk in the European Union: focus on heterogeneous, nonmonotonic data. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 218-230.	1.3	6
8	Tools to evaluate pharmacokinetics data for establishing maximum residue limits for approved veterinary drugs: examples from JECFA's work. Drug Testing and Analysis, 2016, 8, 565-571.	2.6	11
9	Low inÂvitro permeability of the cyanotoxin microcystin-LR across a Caco-2 monolayer: With identification of the limiting factors using modelling. Toxicon, 2014, 91, 5-14.	1.6	11
10	Low or High Doses of Cefquinome Targeting Low or High Bacterial Inocula Cure Klebsiella pneumoniae Lung Infections but Differentially Impact the Levels of Antibiotic Resistance in Fecal Flora. Antimicrobial Agents and Chemotherapy, 2014, 58, 1744-1748.	3.2	37
11	Permeability of dihydro- and cysteine-brevetoxin metabolites across a Caco-2 cell monolayer. Harmful Algae, 2014, 32, 22-26.	4.8	4
12	Comparative Cytotoxicity, Oxidative Stress, and Cytokine Secretion Induced by Two Cyanotoxin Variants, Microcystin LR and RR, in Human Intestinal Cacoâ€2 Cells. Journal of Biochemical and Molecular Toxicology, 2013, 27, 253-258.	3.0	24
13	Comparison of the oral bioavailability and tissue disposition of monensin and salinomycin in chickens and turkeys. Journal of Veterinary Pharmacology and Therapeutics, 2012, 35, 73-81.	1.3	15
14	Implementation and assessment of the quality management system in research in a laboratory of the French Food Safety Agency: application to PhD student work. Accreditation and Quality Assurance, 2009, 14, 207-217.	0.8	3
15	Bioavailability, distribution and depletion of monensin in chickens. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 451-456.	1.3	17
16	Cytochrome P450â€dependent metabolism of monensin in hepatic microsomes from chickens and turkeys. Journal of Veterinary Pharmacology and Therapeutics, 2008, 31, 584-586.	1.3	8
17	Liquid chromatography–electrospray tandem mass spectrometric method for quantification of monensin in plasma and edible tissues of chicken used in pharmacokinetic studies: Applying a total error approach. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2007. 850. 15-23.	2.3	31